Results 41 to 50 of about 4,426 (152)

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis

ClinicoEconomics and Outcomes Research, 2017
George Dranitsaris,1 Lesley G Shane,2 Mark Crowther,3 Guillaume Feugere,4 Seth Woodruff2 1Health Economic and Outcomes Research, Augmentium Pharma Consulting Inc, Toronto, ON, Canada; 2Pfizer Inc, New York, NY, USA; 3McMaster University, Hamilton, ON ...
Dranitsaris G, Shane LG, Crowther M, Feugere G, Woodruff S   +4 more
doaj  

Dalteparin as a Novel Therapeutic Agent to Prevent Diabetic Encephalopathy by Targeting Oxidative Stress and Inflammation

Basic and Clinical Neuroscience, 2020
Introduction: Hepcidin is the main modulator of systemic iron metabolism, and its role in the brain has been clarified recently. Studies have shown that hepcidin plays an important role in neuronal iron load and inflammation.
Motahareh Zeinivand, Arezo Nahavandi, Tourandokht Baluchnejadmojarad, Mehrdad Roghani, Fereshteh Golab   +4 more
doaj  

Paroxysmal Nocturnal Haemoglobinuria‐Associated Acute Cutaneous Thrombosis and Haemolysis in the Setting of Parvovirus B19 and Varicella Zoster Virus Infection

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT A 28‐year‐old male with paroxysmal nocturnal haemoglobinuria (PNH) presented with headache, nasal bridge discomfort and haemoglobinuria. He developed a macular‐papular rash which rapidly progressed into purpura, necrosis and peri‐orbital oedema. Investigations demonstrated severe haemolytic anaemia and acute parvovirus B19 infection.
Louise J. Potter, Roochi Trikha, Shreyans Gandhi, Joanne Large, Tanya N. Basu, Jeanne Boissiere, Hannah Devine, Taku Sugai, Aushna Rasool, Austin Kulasekararaj   +9 more
wiley   +1 more source

A Multicenter, Double‐Blind, Placebo‐Controlled, Randomized Clinical Trial of Oral Anticoagulation in Systemic Sclerosis‐Related Pulmonary Arterial Hypertension—Results From the SPHInX Study

Pulmonary Circulation, Volume 16, Issue 2, April 2026.
ABSTRACT The SPHInX study is the first‐ever randomized controlled trial (RCT) seeking to inform an area of equipoise regarding the efficacy of oral anticoagulation as adjunct therapy in systemic sclerosis‐related pulmonary arterial hypertension (SSc‐PAH).
Mandana Nikpour, Alicia Calderone, Susanna M. Proudman, Dylan Hansen, Eli Gabbay, Nathan Dwyer, Gregory Keir, Vivek Thakkar, Peter K. K. Wong, Anne Keogh, Andrew Burns, David Prior, Harshal Nandurkar, David S. Celermajer, Joanne Sahhar, Rachelle Buchbinder, Wendy Stevens   +16 more
wiley   +1 more source

Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents

Cancer, Volume 132, Issue 6, 15 March 2026.
Abstract Background Pharmacokinetic studies suggest that specific prostate cancer therapies may alter the metabolism of direct oral anticoagulants (DOACs), leading to elevated risks of thrombosis or bleeding. Methods To assess the risk of thrombosis or bleeding, population‐based, retrospective, parallel analyses were conducted in Ontario and Alberta ...
Tzu‐Fei Wang, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont, Cynthia Wu, Pietro Ravani, Dominick Bossé, Robert Talarico, Marc Carrier, Manish M. Sood   +10 more
wiley   +1 more source

Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study

Haematologica, 2006
The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an ...
E Tincani, C Mannucci, B Casolari, F Turrini, MA Crowther, D Prisco, AM Cenci, M Bondi   +7 more
doaj  

Asundexian Versus Apixaban in Patients With Atrial Fibrillation

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background Anticoagulation therapy is central to the prevention of thromboembolic disorders but is limited by bleeding complications associated with traditional agents such as warfarin and direct oral anticoagulants (DOACs). Factor XIa inhibition has emerged as a novel strategy aimed at reducing thrombotic risk while preserving hemostasis ...
Zara Saeed, Syeda Ariba Zehra, Sumyya Tariq, Rocio Pun Zumaran, Mounika Kotte, Zeeshan Hameed, Neeraj Joshi, Pushpa Kumari, Kanta Kumari, Awais Habib, Fawad Talat, Osama Taj, Jahanzeb Malik, Abida Perveen   +13 more
wiley   +1 more source

Improved Effect of an Antiangiogenic Tyrosine Kinase Inhibitor (SU5416) by Combinations with Fractionated Radiotherapy or Low Molecular Weight Heparin

Neoplasia: An International Journal for Oncology Research, 2003
The effect of combining SU5416 with fractionated radiotherapy or with low molecular weight (LMW) heparin (dalteparin) was studied in U87 human glioblastoma xenografts in nude mice.
Eva L. Lund, Minna W.B. Olsen, Kenneth E. Lipson, Gerald McMahon, Anthony R. Howlett, Paul E.G. Kristjansen   +5 more
doaj   +1 more source

Low‐Molecular‐Weight Heparin for Adult ICU Patients Who Require Thromboprophylaxis: Protocol for the INCEPT‐Thromboprophylaxis Platform Trial Domain

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 3, March 2026.
ABSTRACT Background Low‐molecular‐weight heparin (LMWH) is recommended for thromboprophylaxis in adult intensive care unit (ICU) patients. Despite its widespread use, there is insufficient evidence on the optimal dose, and there appears to be practice variation.
Ruben Eck, Anders Granholm, Aske Tøgern, Aksel Karl Georg Jensen, Sandra Jonmarker, Fredrik Sjövall, Karina Meijer, Maria Cronhjort, Morten Hylander Møller, Anders Perner, Frederik Keus   +10 more
wiley   +1 more source